Clinical Trial Detail

NCT ID NCT03574753
Title Lung-MAP S1400K: c-MET Positive
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Southwest Oncology Group
Indications

lung squamous cell carcinoma

Therapies

Telisotuzumab vedotin

Age Groups: adult senior

No variant requirements are available.